News & Updates
Filter by Specialty:
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
In the final progression-free survival (PFS) analysis of the GEMSTONE-301 study, sugemalimab demonstrated sustained efficacy and safety as consolidation treatment for individuals with unresectable stage III non-small cell lung cancer (NSCLC) whose disease had not progressed following either concurrent chemoradiotherapy (cCRT) or sequential CRT (sCRT).
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
07 Oct 2022
Dapagliflozin prevents worsening heart failure, CV death
Dapagliflozin is a safe treatment to reduce the risk of worsening heart failure (HF) or cardiovascular death both in patients with and without history of recent HF hospitalization, a study has shown.
Dapagliflozin prevents worsening heart failure, CV death
06 Oct 2022
Post-exposure doxycycline prevents STIs in MSM, TGW with HIV or on PrEP
Doxycycline, taken with 72 hours of unprotected sex, could prevent sexually transmitted infections (STIs) in men who have sex with men (MSM) or transgender women (TGW) who are either living with HIV (PLHIV) or are receiving pre-exposure prophylaxis (PrEP), according to a study presented at AIDS 2022.
Post-exposure doxycycline prevents STIs in MSM, TGW with HIV or on PrEP
05 Oct 2022
Niraparib maintenance boosts PFS in advanced ovarian cancer
Maintenance therapy with the PARP* inhibitor niraparib led to a sustained and durable progression-free survival (PFS), regardless of biomarker status, in patients with primary advanced ovarian cancer who responded to platinum-based chemotherapy, an updated analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial has shown.
Niraparib maintenance boosts PFS in advanced ovarian cancer
05 Oct 2022
Deucravacitinib bestows benefits in Asian patients with plaque psoriasis
The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.